gemcitabine has been researched along with Neutropenia in 358 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (5.59) | 18.2507 |
| 2000's | 176 (49.16) | 29.6817 |
| 2010's | 138 (38.55) | 24.3611 |
| 2020's | 24 (6.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Björn, N; Brandén, E; De Petris, L; Gréen, H; Jakobsen, I; Koyi, H; Lewensohn, R; Udagawa, C; Zembutsu, H | 1 |
| Ambrosio, AJ; Birrer, MJ; Bradley, C; Konstantinopoulos, PA; Krasner, CN; Matulonis, UA; Penson, RT; Whalen, CA | 1 |
| Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Muneta, M; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y | 1 |
| Achreja, A; Animasahun, O; Chinnaiyan, AM; Choppara, S; Crysler, O; Dippman, D; Enzler, T; Griffith, KA; Gunchick, V; Hsiehchen, D; Kumar-Sinha, C; Mohan, A; Nagrath, D; Nenwani, M; Sahai, V; Wuchu, F; Zalupski, MM; Zhen, DB | 1 |
| Abrams, TA; Biller, LH; Bollenrucher, N; Brais, LK; Cardot-Ruffino, V; Cleary, JM; Delius, L; Dougan, M; Dougan, SK; Enzinger, PC; Keheler, CE; McCleary, NJ; Ng, K; Patel, AK; Perez, K; Remland, J; Rubinson, DA; Schlechter, B; Singh, H; Slater, S; Sullivan, KM; Wang, SJ; Wolpin, BM; Yurgelun, MB | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kimura, Y; Morizane, S; Nishikawa, R; Takenaka, A; Teraoka, S; Yumioka, T | 1 |
| Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C | 1 |
| Chen, T; Choy, E; Cote, GM; Demetri, G; George, S; Marino-Enriquez, A; Merriam, P; Morgan, J; Nathenson, MJ; Thornton, K; Wagner, AJ | 1 |
| Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Fujimiya, T; Kurihara, T; Nagatani, A; Ogawa, Y; Sasaki, H; Sasaki, T; Sunaga, T; Takahashi, N; Watanabe, T; Yamagishi, M | 1 |
| Apellániz-Ruiz, M; Björn, N; Brandén, E; De Petris, L; Gréen, H; Koyi, H; Lewensohn, R; Lundeberg, J; Pradhananga, S; Rodríguez-Antona, C; Sigurgeirsson, B; Svedberg, A | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Kobayashi, M; Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Furukawa, K; Gocho, T; Onda, S; Sakamoto, T; Shiba, H; Shiozaki, H; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Hayuka, K; Murakami, A; Nishiuchi, T; Okano, K; Okita, Y; Okuyama, H; Suzuki, Y; Tsuji, A | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Cao, YB; Li, Q; Ma, YX; Sun, Y; Xu, CA; Zhang, XW | 1 |
| Ando, R; Hotta, Y; Kimura, K; Kondo, M; Yasui, T | 1 |
| Li, J; Liu, Y; Wang, Z; Yang, L; Zhai, X; Zheng, Q; Zhu, Y | 1 |
| Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
| Hirai, K; Inoue, K; Itoh, K; Kawasaki, Y; Matsumoto, M; Nakamori, H; Osada, M; Otake, A; Taku, K; Tsuji, D; Yokoi, M | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Aono, T; Masuda, N; Matsunami, N; Mizutani, M; Nakayama, T; Nishida, Y; Ooe, A; Tanaka, S; Tanino, H; Tokunaga, S; Tsurutani, J; Tsuyuki, S; Yamaguchi, M; Yamamoto, D; Yamamura, J; Yasojima, H; Yoshidome, K | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Kwon, WA; Lee, JW; Oh, TH; Park, SC; Seo, IY | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Fløtten, Ø; Grønberg, BH; Kristensen, A; Solheim, TS | 1 |
| Aujla, PK; Beckett, LA; Lara, PN; Li, Y; Pan, CX; Parikh, M; Robles, DA | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Avigdor, A; Kedmi, M; Nagler, A; Ribakovsky, E; Zlotnick, M | 1 |
| Ishizuka, Y; Nakamichi, H; Sasano, T; Shiokawa, M; Tokou, U; Tsuji, D; Yabe, K; Yamamoto, K; Yoneda, T | 1 |
| Crona, DJ; Denning, S; Etheridge, AS; Furukawa, Y; Hatch, AJ; Hurwitz, HI; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, HL; Niedzwiecki, D; Nixon, AB; Owzar, K; Ratain, MJ; Sibley, AB; Watson, D | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW | 1 |
| Ando, T; Kameda, R; Kobayashi, S; Ohkawa, S; Ueno, M | 1 |
| Assadourian, S; Barone, C; Hatteville, L; Humblet, Y; Karasek, P; Manges, R; Philip, PA; Riess, H; Rougier, P; Santoro, A | 1 |
| Ji, M; Li, J; Zhu, LN | 1 |
| Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Clements, A; Cohn, DE; Smith, B; Straughn, JM; Tierney, BJ | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| Ando, R; Etani, T; Hashimoto, Y; Kawai, N; Kohri, K; Naiki, T; Okada, A; Okamura, T; Tozawa, K; Yasui, T | 1 |
| Jarboe, J; Saif, MW | 1 |
| Shi, X; Yu, XM; Zhang, YP; Zhao, J | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Daignault, S; Healy, P; O'Malley, M; Ramnath, N | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Barton, S; Chau, I; Chua, S; Cunningham, D; Dearden, C; Ethel, M; Hawkes, EA; Horwich, A; Peckitt, C; Potter, M; Wotherspoon, A | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Kaniwa, N; Knights, J; Ramanathan, M; Saito, Y; Sato, Y; Ueno, H | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Akamatsu, H; Endo, M; Imai, H; Kenmotsu, H; Murakami, H; Naito, T; Ono, A; Shukuya, T; Taira, T; Takahashi, T; Tokito, T; Yamamoto, N | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Di, G; Hu, X; Hu, Z; Liu, G; Liu, Y; Shao, Z; Wang, B; Wang, L; Wang, Z; Wu, J; Yang, W; Zhang, J | 1 |
| André, T; Assenat, E; Blanc, JF; Boucher, E; Cervera, P; de la Fouchardière, C; Dollinger, M; Ducreux, M; Faivre, S; Fartoux, L; Foulon, S; Grenier, J; Greten, TF; Hahn, P; Hammel, P; Heinemann, V; Herrmann, T; Malka, D; Pignon, JP; Rosmorduc, O; Rousseau, V; Seufferlein, T; Trarbach, T; Viret, F; Wendum, D | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
| Attygalle, A; Barton, S; Chau, I; Chua, S; Cunningham, D; Dearden, C; Ethell, M; Gleeson, M; Hawkes, EA; Horwich, A; Peckitt, C; Potter, M; Wotherspoon, A | 1 |
| Ajiki, T; Eguchi, H; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kubo, S; Morita, S; Nagano, H; Sakai, D; Seo, S; Takemura, S; Taura, K; Terajima, H; Toyokawa, H; Tsuji, A; Yanagimoto, H | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Beijnen, JH; Crombag, MR; de Vries Schultink, AH; Huitema, AD; Schellens, JH | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Konishi, K; Marubashi, S; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K; Yoshioka, Y | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Amorin, S; Brice, P; Deau, B; Guillermin, Y; Harel, S; Lebras, L; Michallet, AS; Reynes, C; Salles, G; Subtil, F | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Akahori, T; Kawaguchi, C; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Sho, M; Tanaka, T; Yasuda, S | 1 |
| Besse, B; Blackhall, F; Brandén, E; de Petris, L; Edsgärd, D; Gréen, H; Hasmats, J; Koyi, H; Kupershmidt, I; Lewensohn, R; Lindgren, A; Lundeberg, J; Peterson, C; Vikingsson, S | 1 |
| Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L | 1 |
| Ishii, M; Kitamura, K; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Shimizu, S; Yoneyama, K; Yoshida, H | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Hirooka, S; Inoue, K; Kon, M; Kotsuka, M; Matsui, Y; Michiura, T; Ryota, H; Satoi, S; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Betz, BL; Camelo-Piragua, S; Cao, Y; Heth, J; Junck, L; Kim, CJ; Kim, MM; Lawrence, TS; Mammoser, A; Normolle, D; Sagher, O; Schipper, M; Tao, Y; Tsien, CI | 1 |
| Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
| Argnani, L; Chiappella, A; Corradini, P; Degl'Innocenti, D; Dodero, A; Monaco, F; Pellegrini, C; Salvi, F; Vitolo, U; Zinzani, PL | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Chong, S; Han, YH; Kim, HJ; Kim, JW; Kim, MH; Lee, HR; Shin, SH; Sohn, KY; Yoo, N; Yoon, SY | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Chuman, H; Hatano, H; Hiraga, H; Hosaka, M; Iwamoto, Y; Joyama, S; Kaya, M; Kubo, T; Morioka, H; Nagano, A; Nishida, Y; Takahashi, M; Tanaka, K; Toguchida, J; Tsumura, H; Yoshikawa, H | 1 |
| Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Miyazawa, M; Okada, KI; Shimizu, A; Ueno, M; Yamaue, H | 1 |
| Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M | 1 |
| Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Aghajanian, CA; Fury, M; Gerst, S; Goss, TL; Hensley, ML; Konner, J; Larkin, J; Orlando, M; Sabbatini, P; Tai, DF | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yoshida, H | 1 |
| Arcamone, M; Ballerini, PF; Becchimanzi, C; Capobianco, G; Corazzelli, G; De Chiara, A; Frigeri, F; Iannitto, E; Marcacci, G; Pinto, A; Russo, F | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Bulusu, R; Camilleri, D; Follows, G; Marcus, R; Raj, S; Stafford, G; Todd, T; Williams, M | 1 |
| Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Morita, S; Nishimura, T; Sasaki, T; Yanagihara, K; Yasuda, H; Yazumi, S | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Funai, K; Itaya, T; Mochizuki, T; Momiki, S; Nakamura, T; Neyatani, H; Sasaki, K; Suzuki, K; Takahashi, T; Takamochi, K; Toyoda, F; Yong-Il, K | 1 |
| Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
| Angel, J; Athanasiou, A; Karanikas, C; Kosmas, C; Lampaki, S; Mylonakis, N; Politis, N; Rapti, A; Ziras, N | 1 |
| Byun, JH; Hwang, IG; Jang, JS; Kim, BS; Kim, SY; Kim, YH; Lee, KH; Lee, MA; Lee, SJ; Lim, HY; Oh, SC; Oh, SJ; Park, E; Song, HS; Yoo, N; Yoon, S | 1 |
| Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Arimoto, T; Hiramatsu, A; Hosogi, S; Iwasaki, Y; Kohno, Y; Koyama, Y; Marunaka, Y; Nakanishi, M; Tamiya, N; Ueda, M | 1 |
| Matsuzawa, H; Suemitsu, R; Takeo, S; Yamaguchi, M | 1 |
| Besova, NS; Borisov, VI; Bychkov, MB; Chitiia, LV; Filatova, LV; Garin, AM; Gershanovich, ML; Gorbunova, VA; Gurov, SN; Makhnova, EV; Nebol'sin, VE; Raĭkhlin, NT; Sitdikova, SM; Topchieva, SV; Treshchalina, EM; Verebnikova, NV | 1 |
| Bossard, N; Chauffert, B; Girard, N; Mornex, F; Wautot, V; Ychou, M | 1 |
| Anthoney, A; Bridgewater, J; Cunningham, D; Hughes, S; Iveson, T; Madhusudan, S; Maraveyas, A; Palmer, DH; Pereira, SP; Roughton, M; Valle, J; Wasan, H | 1 |
| Amundsen, T; Bremnes, RM; Fløtten, O; Grønberg, BH; Hjelde, HH; Jordhøy, M; Kaasa, S; Plessen, Cv; Sundstrøm, S | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Aerts, JG; Hoogsteden, HC; Legrand, C; Schmitz, PI; Surmont, V; Tan, KY; Tournoy, K; van Klaveren, RJ; van Meerbeeck, JP; Vernhout, RM | 1 |
| Benson, AB; Bentrem, DJ; Mulcahy, MF; Rademaker, A; Small, W; Talamonti, MS; Weitner, BB | 1 |
| Ashley, S; Brunetto, AT; Carden, CP; Faria, AL; Myerson, J; O'Brien, ME; Popat, S | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Cohen, DJ; Hochster, HS; Levinson, B; Love, E; Nicol, SJ; Yaw, M; Yuan, Y | 1 |
| Christos, P; Espinoza-Delgado, I; Hamel, N; Kaubish, A; Lane, ME; Matulich, D; Ocean, AJ; Siegel, A; Sparano, JA; Sung, M; Ward, MM; Yen, Y | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Chaigneau, L; Chargari, C; Clavreul, G; Dumanoir, C; Jacquin, JP; Magné, N; Mélis, A; Merrouche, Y; Mille, D; Nourissat, A; Orfeuvre, H; Savary, J; Thorin, J | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Saito, Y | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Azzarello, D; Bottari, M; Maisano, M; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M | 1 |
| Fujii, M; Harada, R; Hirao, K; Ishida, E; Kato, H; Kawamoto, H; Kurihara, N; Mizuno, O; Noma, Y; Ogawa, T; Sakakihara, I; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL | 1 |
| Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Horai, T; Ikeda, N; Imamura, F; Inoue, A; Kimura, Y; Nishino, K; Nishio, M; Noro, R; Ohsaki, Y; Tsuboi, M; Uchida, J | 1 |
| Ikegami, A; Imawari, M; Inoue, K; Katsumoto, E; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Yoneyama, K; Yoshikumi, H | 1 |
| Alkis, N; Benekli, M; Berk, V; Bilici, A; Colak, D; Coskun, U; Dane, F; Dikilitas, M; Gumus, M; Kaplan, MA; Ozdemir, NY; Ozkan, M | 1 |
| Orlova, RV; Protasova, AE | 1 |
| Hirata, K; Ina, S; Kihara, C; Kimura, Y; Kiyotani, K; Kubo, M; Mitsuhata, N; Mushiroda, T; Nakamura, Y; Takahashi, A; Uno, S; Yamaue, H; Zembutsu, H | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| Bellmunt, J; Boehle, A; Chevreau, C; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Laufman, LR; Marreaud, S; Mead, GM; Paz-Ares, L; Raghavan, D; Skoneczna, I; Sylvester, R; von der Maase, H; Winquist, E | 1 |
| Kamiyama, Y; Kasai, H; Kodama, T; Mori, K | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Hadley, S; Khan, G; Lawrence, T; Leslie, W; Normolle, D; Schipper, M; Simeone, DM; Sonnenday, C; Ten-Haken, R; Zalupski, MM | 1 |
| Cai, W; Chen, Y; Liu, T; Xu, J; Zhang, J; Zhou, Y; Zhuang, R | 1 |
| Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Li, Z; Lu, S; Ren, Z; Yu, Y; Zhang, L; Zhao, J | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Arslan, M; Ceylan, Y; Degirmenci, T; Gunlusoy, B; Kara, C; Kozacıoğlu, Z; Vardar, E | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Hwang, YI; Jang, SH; Jung, KS; Kim, DG; Kim, JH; Kim, SY; Park, S | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Apolo, AB; Bajorin, DF; Balar, AV; Gallagher, DJ; Garcia-Grossman, IR; Iasonos, A; Milowsky, MI; Mironov, S; Ostrovnaya, I; Regazzi, AM; Trout, A | 1 |
| Vogelzang, NJ | 1 |
| Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Philip, PA | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Arquette, MA; Bartlett, NL; Blum, KA; Clark, RS; Fears, CL; Fracasso, PM; Tan, BR | 1 |
| Durgam, S; Levin, M; Novetsky, A | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Barni, S; Beretta, GD; Cascinu, S; Catalano, G; Catalano, V; Ferraù, F; Foa, P; Frontini, L; Graziano, F; Labianca, R; Mare, M; Pancera, G; Priolo, D | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Zaffaroni, N; Zilembo, N | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| Bilgin, T; Ozalp, S; Ozerkan, K; Vardar, MA; Yalçin, OT; Zorlu, G | 1 |
| Baker, M; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Scullin, DC; Shaffer, DW | 1 |
| Casado, V; Dómine, M; Dorta, FJ; Estévez, LG; Florián, J; Jiménez, E; Léon, A; Lobo, F; Lomas, M; López, P; Virizuela, JA | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Eriguchi, N; Funakoshi, A; Ito, T; Migita, Y; Mizumoto, K; Muranaka, T; Niyahara, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
| Chen, A; Grem, JL; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Rowedder, A; Takimoto, CH; Xu, Y | 1 |
| Lénárt, T; Sárosi, V | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Spiridonidis, CH | 1 |
| Eckel, F; Erdmann, J; Lersch, C; Mayr, M; Schmelz, R | 1 |
| Dawson, NA; Edelman, MJ; Houston, J; Lara, PN; Lauder, I; Law, LY; Meyers, FJ | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Toffolatti, L; Zilembo, N | 1 |
| Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Van Bochove, A; Van Groeningen, CJ | 1 |
| Benasso, M; Corvò, R; Pallestrini, E; Ponzanelli, A; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V | 1 |
| Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D | 1 |
| Aghajanian, C; Anderson, S; Bloss, J; Chi, D; Dizon, D; Dupont, J; Leitao, M; O'Flaherty, C; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Satoh, T; Tamura, K; Yamamoto, N | 1 |
| Miles, D; Reichardt, P | 1 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Esper, P; Griffith, KA; Hayman, JA; Herman, JM; Kent, E; Montie, J; Sandler, HM; Smith, DC; Sullivan, MA | 1 |
| André, T; Avenin, D; de Gramont, A; Gayet, B; Hannoun, L; Houry, S; Lotz, JP; Louvet, C; Maindrault-Goebel, F; Paye, F; Provent, S; Rosmorduc, O; Selle, F; Tournigand, C | 1 |
| Daugherty, CK; Huo, D; Janisch, L; Larson, RA; Odenike, OM; Ratain, MJ; Sobecks, RM; Zimmerman, TM | 1 |
| Blackstock, AW; Hollis, DR; Mayer, RJ; Niedwiecki, D; Tempero, MA; Tepper, JE | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Hidaka, S; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tanada, M; Tsubouchi, E; Tsuzuki, T; Yamauchi, Y | 1 |
| A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS | 1 |
| Hermant, P; Jouveshomme, S; Patte, D | 1 |
| Asmar, L; Heaven, R; Ilegbodu, D; Neubauer, M; Olivares, J; Otsuka, A; Paschold, E; Sirridge, C; Tuttle, T | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D | 1 |
| Gatzemeier, U; Groth, G; Nimmermann, C; Reck, M; von Pawel, J | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Nishimoto, H; Ohara, T; Shimada, K | 1 |
| Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L | 1 |
| Jin-Kim, H; Kim, JS; Kim, SH; Kim, YH; Kwon, HC; Oh, SY; Park, JS | 1 |
| Ditto, A; Fontanelli, R; Grijuela, B; Hanozet, F; Kusamura, S; Raspagliesi, F; Scibilia, G; Scollo, P; Solima, E; Spatti, G; Vecchione, F; Zanaboni, F | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Dy, GK; Erlichman, C; Goldberg, RM; Hanson, LJ; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA; Suri, A | 1 |
| Bernardini, I; Chioni, A; Conte, PF; Fabbri, A; Falcone, A; Ferrari, K; Galli, L; Grosso, AM; Innocenti, F; Orlandini, C; Pegna, AL; Ricci, S; Russo, F; Tibaldi, C; Tognarini, L | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T | 1 |
| Botta, M; Bretti, S; Castagneto, B; Dongiovanni, D; Muzio, A; Numico, G; Sinaccio, G; Zai, S | 1 |
| Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O | 1 |
| Ando, S; Iida, T; Kimura, H; Nakajima, T; Suzuki, M | 1 |
| Arning, M; Fuchs, M; John, W; Kindler, HL; Oettle, H; Peeters, M; Ramanathan, RK; Richards, D; van Laethem, JL; Von Hoff, D; Zimmermann, A | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Kuramoto, K; Terao, I | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
| Adjei, AA; Fitch, TR; Hillman, DW; Ingle, JN; Kugler, JW; Ma, CX; Niedringhaus, RD; Perez, EA; Rowland, KM; Steen, P | 1 |
| Lokich, J | 1 |
| Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Chien, PY; Khan, AR; Sheikh, S | 1 |
| Fumoleau, P; Levy, C | 1 |
| Lehoczky, O | 1 |
| Aguilar, EA; Carbonero, AI; Delgado, FJ; Espinosa, JC; García López, JL; García Ribas, I; García, JJ; Guzmán, MC; Jericó, JF; Martos, CF; Mena, AC; Muñoz, ML; Plazas, JG; Rovira, PS; Santasusana, JM; Valera, JS | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Bay, JO; Blay, JY; Brain, E; Bui, NB; Cherix, S; Chevreau, C; Cioffi, A; Coindre, JM; Emile, G; Fayette, J; Isambert, N; Kwiatkowski, F; Le Cesne, A; Leyvraz, S; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Ichinose, Y; Kamei, T; Maruyama, R; Nakamura, T; Nishiyama, K; Okamoto, T; Sakai, M; Suemitsu, R; Wataya, H | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Alloisio, M; Brambilla, G; Campagnoli, E; Cavina, R; Latteri, F; Morenghi, E; Parra, HS; Santoro, A; Torri, W | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Brahmer, J; Ettinger, D; Juergens, R | 1 |
| Cipolat, M; Colantonio, I; Di Costanzo, G; Fea, E; Garrone, O; Gasco, M; Granetto, C; Merlano, M; Numico, G; Occelli, M; Pelissero, A; Russi, EG; Sorrentino, R; Taglianti, RV; Vitiello, R | 1 |
| Beinert, T; Binder, D; Grah, C; Schäper, C; Schweisfurth, H; Siebert, G; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Boku, N; Fukutomi, A; Yoshino, T | 1 |
| Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y | 1 |
| Akbulut, H; Büyükcelik, A; Cay, F; Demirkazik, A; Dincol, D; Icli, F; Isikdogan, A; Onur, H; Utkan, G; Yalcin, B | 1 |
| Bortolotti, L; Breda, C; Favaretto, AG; Loreggian, L; Marulli, G; Rea, F; Sartori, F | 1 |
| Ahuja, HG; Hensing, TA; Hoang, T; Kim, K; Larson, M; McGovern, J; Merchant, J; Oettel, KR; Sanchez, FA; Schiller, JH; Traynor, AM | 1 |
| Bartlett, NL; Canellos, GP; Cheson, BD; Friedberg, JW; Johnson, JL; Johnson, KB; Niedzwiecki, D; van Besien, K; Zelenetz, AD | 1 |
| Yoneda, S | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| El-Rayes, B; Griffith, KA; Kalemkerian, GP; Muler, JH; Philip, PA; Schneider, BJ; Zalupski, MM | 1 |
| Choi, YH; Chung, HC; Jeung, HC; Kim, BS; Rha, SY; Roh, JK; Yang, WI; Yoo, JH | 1 |
| Guo, SS; Jiang, ZM; Liang, HL; Xie, DR; Yang, Q | 1 |
| Huang, MZ; Wang, LR; Zhang, GB | 1 |
| Li, Y; Sun, Y; Zhang, XR | 1 |
| Agelaki, S; Georgoulias, V; Gioulbasanis, I; Ignatiadis, M; Karampeazis, A; Kentepozidis, N; Mavroudis, D; Papadimitraki, E; Vamvakas, L; Vardakis, N | 1 |
| Buesa, JM; Capelan, M; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Jiménez, P; Jiménez-Lacave, A; Llorente, B; Luque, M; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Aoki, H; Iijima, H; Imai, H; Inoue, T; Ishida, E; Ishihara, S; Iwasaki, Y; Kawashima, O; Kobayashi, G; Mori, M; Saito, R; Sato, K; Tomizawa, Y; Watanabe, S; Yamada, H; Yatomi, M | 1 |
| Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN | 1 |
| Fayad, LE; Goy, A; Hagemeister, F; McLaughlin, P; Neelapu, S; Oki, Y; Pro, B; Romaguera, J; Samaniego, F; Younes, A | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Benson, AB; Berlin, J; Chakravarthy, AB; Freedman, GM; Gill, JF; Hoffman, JP; Kinsella, TJ; Konski, AA; Lawrence, T; McGinn, CJ; Merchant, NB; Mulcahy, MF; Nicol, S; Philip, PA; Small, W; Talamonti, MS; Xu, RM; Zalupski, MM | 1 |
| Cooney, MM; Dreicer, R; Li, H; Roth, BJ; Wilding, G | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Bruntsch, U; Catimel, G; Clavel, M; de Mulder, P; Judson, I; Piccart, M; Sessa, C; Vermorken, JB; Verweij, J; Wanders, J | 1 |
| Aamdal, S; Eppelbaum, R; Franklin, H; Sessa, C; Smyth, JF; Sulkes, A; Ten Bokkel Huinink, W; Vermorken, J; Wanders, J; Wolff, I | 1 |
| Kurita, Y; Nakai, Y; Niitani, H; Taguchi, T; Yokoyama, A; Yoneda, S | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Taguchi, T; Takada, Y | 1 |
| Adamo, V; Altavilla, G; Clerici, M; Crinò, L; Cruciani, G; De Marinis, F; Dogliotti, L; Figoli, F; Incoronato, P; Marangolo, M; Mosconi, AM; Oliva, C; Paccagnella, A; Pucci, F; Salvati, F; Santucci, A; Scagliotti, G; Sorbolini, S; Tonato, M; Trippetti, M | 1 |
| Burkes, R; Cormier, Y; Evans, WK; Feld, R; Goss, G; Klimo, P; Shepherd, FA; Taylor, M | 1 |
| Abratt, RP; Bezwoda, WR; Goedhals, L; Hacking, DJ | 1 |
| Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ | 1 |
| Bell, D; Bugat, R; Campbell, L; Friedlander, M; Harnett, P; Kayitalire, L; Millward, MJ; Moreno, JA; Ripoche, V; Varette, C | 1 |
| Albertini, P; Bendandi, M; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Tura, S; Zinzani, PL | 1 |
| Caponigro, F; Costagliola, G; De Marino, V; Dimitri, P; Facchini, G; Ferrante, G; Ferraro, A; Gentile, M; Gravina, A; Iaffaioli, RV; Illiano, A; Marzano, N; Tortoriello, A | 1 |
| Hara, N; Kurita, Y; Matsui, K; Nakai, Y; Niitani, H; Ohhashi, Y; Yokoyama, A | 1 |
| Eady, A; Evans, WK; Gagliardi, A; Kocha, W; Newman, TE | 1 |
| Barón, MG; Castro, J; De la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Girón, CG; López Gómez, L; Madroñal, C; Martínez, B | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Kelly, K | 1 |
| Einhorn, LH; Ng, EW; Robinson, L; Sandler, AB | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Andersen, L; Crinò, L; Dogliotti, L; von der Maase, H; Weinknecht, S | 1 |
| Barreras, L; Cano, R; Davila, E; Krill, E; Lewis, M; Lilenbaum, R; Lutzky, J; Schwartz, M; Siegel, L | 1 |
| Camps, C; Herrero, CC; Jaime, AB; Martínez, EN | 1 |
| Brierre, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Litchy, S | 1 |
| Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE | 1 |
| Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
| Castiglione, F; Cigolari, S; Farris, A; Felletti, R; Frontini, L; Gallo, C; Gasparini, G; Gridelli, C; Gulisano, M; Ianniello, GP; Locatelli, MC; Perrone, F; Piazza, E; Robbiati, SF | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Kosmidis, P | 1 |
| Ettinger, DS | 1 |
| Albertini, P; Bendandi, M; Gherlinzoni, F; Piccaluga, PP; Stefoni, V; Tani, M; Tura, S; Zinzani, PL | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Deutsch, J; Greil, R; Huber, H; Krajnik, G; Malayeri, R; Marhold, F; Mohn-Staudner, A; Pirker, R; Preiss, P; Schäfer-Prokop, C; Schmeikal, S; Thaler, J; Wein, W | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Chang, JW; Chen, SC; Lee, CH; Lin, MC; Tsao, TC; Wang, SW | 1 |
| Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H | 1 |
| Lilenbaum, R | 1 |
| Bast, RC; Booser, D; Esteva, FJ; Esteva, FL; Hortobagyi, GN; Murray, JL; Rahman, Z; Rivera, E; Rosales, MM; Syrewicz, L; Theriault, RL; Valero, V | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Gajra, A; Graziano, SL; Kirshner, J; Mehdi, SA; Newman, N | 1 |
| Bancalari, L; Canessa, P; Fiasella, L; Maggiani, R; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F | 1 |
| Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D | 1 |
| Accurso, V; Agostara, B; Carroccio, R; De Bella, MT; Di Vita, G; Faillú, G; Ferraù, F; Gebbia, V; Leonardi, V; Licata, G; Palmeri, S; Sciortino, G; Spatafora, M; Vaglica, M; Valenza, R; Vitello, S | 1 |
| Blohmer, JU; du Bois, A; Kimmig, R; Lück, HJ; Moebus, V; Pfisterer, J; Quaas, J; Schroeder, W | 1 |
| Ahern, J; Carmichael, J; Dombernowsky, P; Hansen, H; Hansen, M; Harper, PG; Highley, MS; Hirsch, F; Lund, B; Parnis, FX; Underhill, CR; Williams, C | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Jassem, J; Krawczyk, K; Krzakowski, M; Lis, J; Miracki, K; Mozejko-Pastewka, B; Ramlau, R; Roszkowski, K; Szczesna, A; Słomiński, JM | 1 |
| Ahumada, M; Fodor, M; Gallardo, JO; Gamargo, C; Orlandi, L; Rubio, B; Yáñez, M | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N | 1 |
| Ferri-Dessens, RM; Gouva, S; Kleisbauer, JP; Léna, H; Robinet, G; Thomas, P; Vernejoux, JM | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
14 review(s) available for gemcitabine and Neutropenia
| Article | Year |
|---|---|
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2017 |
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic; Vinorelbine | 2018 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Topics: Antineoplastic Agents; Camptothecin; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic | 2011 |
Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Biological; Neutropenia; Platinum Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
Gemcitabine and platinum combinations in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
[Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2005 |
[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neutropenia; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2007 |
The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neutropenia; Patient Selection; Thrombocytopenia; Treatment Outcome | 1999 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
262 trial(s) available for gemcitabine and Neutropenia
| Article | Year |
|---|---|
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2023 |
[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neutropenia; Thrombocytopenia; Treatment Outcome | 2023 |
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neutropenia | 2023 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors | 2020 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Research Design; Sarcoma | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Gemcitabine; Guanidines; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Postoperative Period; Treatment Outcome | 2021 |
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platinum Compounds; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Urologic Neoplasms | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Topics: Administration, Intravenous; Aged; Cytidine Deaminase; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prospective Studies | 2019 |
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Pyridones; Pyrimidinones; Thrombocytopenia; Treatment Outcome | 2013 |
A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2013 |
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2013 |
[Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Chronotherapy; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids | 2013 |
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium; Young Adult | 2014 |
[Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Neutropenia; Pemetrexed; Quality of Life; Survival Rate; Thrombocytopenia; Vomiting | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma; Cetuximab; Cholangiocarcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatectomy; Humans; Male; Neutropenia; Postoperative Care; Pyridines; Tegafur; Treatment Outcome | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Tegafur | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polysaccharides; Survival Analysis; Treatment Outcome | 2016 |
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.
Topics: Adult; Aged; Brain Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Radiotherapy Dosage; Young Adult | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2016 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2017 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting | 2017 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dietary Supplements; Drug Administration Schedule; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Maximum Tolerated Dose; Neoplasms; Neutropenia; Ovarian Neoplasms; Pemetrexed; Treatment Outcome; Vitamin B Complex | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Patient Compliance; Pneumonectomy; Prospective Studies; Thrombocytopenia | 2010 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2010 |
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Neutropenia; Survival Rate | 2009 |
Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Patient Compliance; Treatment Outcome | 2010 |
[Final results of cooperative studies of dicarbamine used as a hemoprotector in combination chemotherapy for cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caproates; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hematinics; Humans; Imidazoles; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2009 |
Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Thrombocytopenia; Tumor Burden; Young Adult | 2010 |
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Patient Compliance; Proportional Hazards Models | 2010 |
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; Young Adult | 2010 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction | 2011 |
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fever; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Patient Dropouts; Pemetrexed; Pyrimidines; Renal Insufficiency; Severity of Illness Index; Young Adult | 2011 |
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Fine-Needle; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatic Insufficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Pyridines; Ribonucleotide Reductases; RNA, Messenger; Survival Analysis; Thiosemicarbazones | 2011 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Injections, Intravenous; Middle Aged; Neutropenia; Polyethylene Glycols; Stomatitis; Thrombocytopenia; Treatment Outcome | 2012 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taiwan | 2011 |
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Watchful Waiting | 2011 |
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2011 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organs at Risk; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Time Factors | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome | 2012 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
[The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Constipation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Neoplasms; Neutropenia; Stomatitis; Treatment Outcome | 2002 |
Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2002 |
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Survival; Thrombocytopenia; Treatment Outcome | 2003 |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia; Treatment Outcome; Tumor Cells, Cultured | 2003 |
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Recurrence; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Vinblastine; Vinorelbine | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
[Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Exanthema; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Vomiting, Anticipatory | 2003 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quality of Life; Thrombocytopenia; Treatment Outcome | 2003 |
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Urologic Neoplasms | 2004 |
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 2004 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Tegafur; Uracil | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fever; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Squamous Cell; Neutropenia; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome | 2004 |
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones | 2004 |
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Thrombocytopenia | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Surveys and Questionnaires; Thrombocytopenia; Urinary Bladder Neoplasms | 2004 |
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2004 |
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis | 2003 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
[Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Fever; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Primary Health Care; Prospective Studies; Vinblastine; Vinorelbine | 2004 |
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome | 2004 |
[Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Tirapazamine; Triazines | 2004 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2004 |
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome | 2004 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Pemetrexed | 2005 |
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cytidine Deaminase; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Exanthema; Fatigue; Floxuridine; Gemcitabine; Genotype; Humans; Japan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Stomatitis; Thrombocytopenia; Treatment Outcome | 2005 |
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Survival Analysis; Thrombocytosis; Treatment Outcome | 2005 |
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neutropenia | 2005 |
Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pemetrexed; Survival Analysis | 2006 |
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Hyperbilirubinemia; Infusions, Intravenous; Male; Middle Aged; Mucositis; Neutropenia; Pancreatic Neoplasms; Patient Compliance; Quality of Life; Spain; Survival Analysis; Treatment Outcome | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2007 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Vinblastine; Vinorelbine | 2007 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2007 |
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Thromboembolism; Vomiting, Anticipatory | 2007 |
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Pleural Neoplasms; Pneumonectomy; Radiation Dosage; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Time Factors | 2007 |
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sulindac; Survival Analysis; Treatment Outcome; Vomiting | 2006 |
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Hodgkin Disease; Humans; Middle Aged; Neutropenia; Patient Selection; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 2007 |
A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Leukopenia; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2007 |
[Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2007 |
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pain; Rituximab; Survival Analysis; Treatment Outcome | 2008 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome; Vomiting | 2008 |
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neutropenia; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Squamous Cell; Deoxycytidine; Europe; Fatigue; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Liver; Male; Middle Aged; Neutropenia; Remission Induction | 1994 |
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neutropenia; Stomach Neoplasms | 1994 |
[A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase II].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies | 1997 |
Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia; Treatment Outcome | 1997 |
Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Treatment Outcome | 1997 |
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fever; Gemcitabine; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Quality of Life; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neutropenia; PUVA Therapy; Remission Induction; Safety; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 1998 |
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia | 1999 |
[Phase I study of gemcitabine hydrochloride (LY 188011) combination therapy with cisplatin in the patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting, Anticipatory | 1999 |
Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Peripheral Nervous System Diseases; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Urologic Neoplasms | 1999 |
Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion, Malignant; Remission Induction; Survival Rate; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Pemetrexed | 2000 |
Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Phase II study of regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2000 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2001 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Gemcitabine; Humans; Liposomes; Middle Aged; Neutropenia | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyponatremia; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Nervous System Diseases; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
A phase II study of gemcitabine in gallbladder carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fever; Gallbladder Neoplasms; Gemcitabine; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematuria; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urination Disorders; Urologic Neoplasms | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |
Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platelet Count; Thrombocytopenia; Vomiting | 2002 |
Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vomiting | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
84 other study(ies) available for gemcitabine and Neutropenia
| Article | Year |
|---|---|
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Neoplasms; Neutropenia; Sweden | 2022 |
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2023 |
Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcopenia; Thrombocytopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2020 |
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin.
Topics: Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neutropenia; Odds Ratio; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia; Urologic Neoplasms | 2020 |
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Exome Sequencing; Gemcitabine; Genome-Wide Association Study; Humans; Leukopenia; Lung Neoplasms; Neutropenia | 2020 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2021 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Male; Middle Aged; Nephrectomy; Neutropenia; Retrospective Studies; Urinary Bladder Neoplasms | 2017 |
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Pemetrexed; Platinum; Retrospective Studies; Taxoids | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2017 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Factors that Predict Neutropenia in Korean Patients with Advanced Urothelial Cancer after Cisplatin- Based Systemic Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Leukocyte Count; Methotrexate; Middle Aged; Neutropenia; Neutrophils; Republic of Korea; Risk Factors; Urologic Neoplasms; Vinblastine | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Positron Emission Tomography Computed Tomography; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hospitalization; Humans; Models, Econometric; Neutropenia; Uterine Cervical Neoplasms | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2013 |
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Survival Analysis; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2014 |
Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity.
Topics: 5-Lipoxygenase-Activating Proteins; Antimetabolites, Antineoplastic; Asian People; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Gene-Environment Interaction; Genetic Markers; Genome-Wide Association Study; Genome, Human; Genotype; Humans; Models, Genetic; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Signal Transduction | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2015 |
Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Services for the Aged; Humans; Incidence; Male; Middle Aged; Netherlands; Neutropenia; Retrospective Studies | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancreatic Neoplasms | 2014 |
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Hypersensitivity; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Neutropenia; Polyethylene Glycols; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Cell Count; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Smoking; Treatment Outcome | 2015 |
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Thrombocytopenia | 2016 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Ifosfamide; Induction Chemotherapy; Kaplan-Meier Estimate; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neutropenia; Platinum; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure | 2015 |
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Topics: Animals; Biomarkers; Cell Movement; Deoxycytidine; Diglycerides; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Leukocyte Count; Mice, Inbred BALB C; Neutropenia; Neutrophils; Polyethylene Glycols; Receptors, Interleukin-8B; Recombinant Proteins; Time Factors | 2016 |
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Gemcitabine; Humans; Japan; Middle Aged; Neutropenia; Osteosarcoma; Pneumonia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome; Tubulin Modulators; Young Adult | 2016 |
A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neutropenia; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Cholangitis; Cholecystitis; Cholestasis; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Prosthesis Design; Prosthesis-Related Infections; Retrospective Studies; Stents; Time Factors; Treatment Outcome | 2008 |
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Humans; Logistic Models; Male; Mass Spectrometry; Middle Aged; Neutropenia; Pancreatic Neoplasms; Phenotype; Thrombocytopenia | 2009 |
Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult | 2009 |
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2009 |
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Odds Ratio; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2012 |
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Taxoids; Thrombocytopenia | 2012 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Topics: Aged; Apoptosis Regulatory Proteins; Biomarkers, Pharmacological; Calcium-Calmodulin-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Death-Associated Protein Kinases; Deoxycytidine; Female; Gemcitabine; Genome-Wide Association Study; Genotype; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Risk Factors | 2012 |
High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Topics: Adult; Aged; Asian People; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Humans; Male; Middle Aged; Mutation; Neoplasms; Neutropenia; Polymorphism, Genetic | 2012 |
[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Constipation; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomatitis; Vinblastine; Vinorelbine | 2012 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
[Gemcitabine-cisplatin combination in the first line treatment of non-small cell lung cancer. Our experience and analysis of safety].
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Constipation; Creatinine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Eruptions; Dyspnea; Female; Gemcitabine; Hemoglobins; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies; Severity of Illness Index; Taste Disorders; Thrombocytopenia; Treatment Outcome | 2003 |
Special patients, special treatments.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Fever; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Population Dynamics; Taxoids | 2003 |
Setting the record straight: activity of gemcitabine monotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Survival Rate | 2004 |
[Cisplatin schedule in combination with gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Length of Stay; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia | 2005 |
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; HT29 Cells; Humans; Leukemia P388; Leukocyte Count; Mice; Mice, SCID; Neutropenia; Nucleoside Transport Proteins; Pancreatic Neoplasms; Thioinosine; Xenograft Model Antitumor Assays | 2006 |
Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drainage; Drug Administration Schedule; Female; Gemcitabine; Heart Neoplasms; Humans; Mesothelioma; Middle Aged; Neutropenia; Pericardial Effusion; Remission Induction; Survivors; Vinblastine; Vinorelbine | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Pharyngeal Neoplasms; Stomatitis | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Haplotypes; Humans; Middle Aged; Neutropenia; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins | 2007 |
[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Thrombocytopenia | 2007 |
[Clinical characteristics and chemotherapy of advanced-stage bronchioloalveolar carcinoma of the lung: report of 53 patients].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Retrospective Studies; Sex Factors; Smoking; Vinblastine; Vinorelbine | 2007 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors | 2000 |
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mucous Membrane; Neutropenia; Thrombocytopenia; Treatment Outcome | 2001 |
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |